Catalog No.
Product Name
Application
Product Information
Citations
-
HMG-CoA reductase inhibitor
Atorvastatin is an HMG-CoA reductase inhibitor (IC50 = 154 nM) that is effective in treating hypercholesterolemia and certain dyslipidemias.- Huang Y, .et al. , Mol Med Rep, 2016, Feb;13(2):1888-94 PMID: 26707502
-
HMG-CoA reductase inhibitor
Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis.- Weizhen Chen, .et al. , Biomaterials, 2021, 280:121260 PMID: 34823885
- Karis Tutuska, .et al. , Cell Death Dis, 2020, Apr; 11(4): 274 PMID: 32332697
- D Jarmuzek, .et al. , J Photochem Photobiol A Chem, 2019, November
- Marwan Ibrahim Abdullah, .et al. , Sci Rep, 2017, 7: 8090 PMID: 28808351
-
HMG-CoA reductase inhibitor
Rosuvastatin is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. -
HMG-CoA Reductase inhibitor
Clinofibrate is a lipid clearing agent that appears to modify lipid metabolism, diminishing the steroid induced accumulation of lipids within osteocytes. It also can effectively reduce the plasma fibrinogen level.
-
HMG-CoA reductase inhibitor
Atorvastatin (Lipitor) is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol. -
HMG-CoA reductase inhibitor
Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent). -
HMG-CoA reductase inhibitor
Pravastatin sodium is a water-soluble, competitive inhibitor of 3-hydroxy-3-methyl coenzyme A (HMG-CoA) reductase. Potently blocks cholesterol synthesis in vivo (Ki~ 1 nM) and displays cardioprotective properties. -
HMG-CoA reductase inhibitor
Swertiamarin has shown potential as antiatherogenic agent by inhibiting HMG-CoA reductase activity in high cholesterol fed rats. -
CoA reductase inhibitor
Atorvastatin, (+/-)- is a Hydroxymethylglutaryl-CoA reductase inhibitor. -
HMG-CoA reductase inhibitor
Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. -
HMG-CoA reductase inhibitor
2-Hydroxy atorvastatin calcium salt is a hydroxy metabolite of Atorvastatin calcium salt. Atorvastatin is a potent HMG-CoA reductase inhibitor with an IC50 value of 8 nM. -
Cholesterol biosynthesis inhibitor
Monacolin J is an inhibitor of cholesterol biosynthesis, and inhibits the activity of HMG-CoA reductase. -
HMG-CoA reductase inhibitor
Pitavastatin Lactone is an HMG-CoA reductase inhibitor. -
HMG-CoA Inhibitor
HMG499 is a potent and selective inhibitor of HMG-CoA reductase, exhibiting an IC50 of 0.41 μM. This compound effectively reduces serum cholesterol levels and mitigates the statin-induced accumulation of HMGCR, making it a valuable tool for research in lipid metabolism and atherosclerosis. HMG499 is relevant for studies investigating cholesterol regulation and cardiovascular disease pathways. -
HMG-CoA Reductase Inhibitor
Atorvastatin hemicalcium trihydrate is an orally active inhibitor of HMG-CoA reductase, primarily utilized in the management of dyslipidemia by effectively lowering blood lipid levels. Additionally, it demonstrates inhibitory effects on human smooth muscle cell proliferation and invasion, with IC50 values of 0.39 μM and 2.39 μM, respectively. This compound is valuable for research focused on atherosclerosis, cardiovascular diseases, and cell growth regulation. -
HMG-CoA reductase inhibitor
Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. -
HMG-CoA reductase inhibitor
Rosuvastatin (Crestor) is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar to that of other statins. -
HMG-CoA reductase inhibitor
Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM. -
HMG-CoA Reductase Inhibitor
Pitavastatin sodium is a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase, significantly reducing cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. This compound serves as an effective inducer of low-density lipoprotein-cholesterol (LDL-C) receptors in hepatocytes. In addition to its primary role in cholesterol regulation, pitavastatin sodium exhibits various biological activities, including anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects, making it valuable for diverse research applications in lipid metabolism and disease. -
HMG-CoA Reductase (HMGCR) Inhibitor
Pravastatin is a competitive inhibitor of HMG-CoA reductase (HMGCR), playing a critical role in the regulation of cholesterol biosynthesis. With an IC50 value of 5.6 μM, it effectively reduces cholesterol levels and is commonly utilized in cardiovascular research. This compound is valuable for studies investigating lipid metabolism and the pharmacological modulation of cholesterol levels in various biological systems. -
HMG-CoA Reductase Inhibitor
Cerivastatin is a highly potent HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. This synthetic lipid-lowering agent effectively reduces low-density lipoprotein cholesterol levels. In addition to its lipid-modulating effects, Cerivastatin has exhibited inhibitory effects on the proliferation and invasiveness of MDA-MB-231 breast cancer cells, primarily through the inhibition of RhoA signaling, indicating potential applications in cancer research. -
HMG-CoA Reductase Inhibitor
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect. -
HMG-CoA Reductase Inhibitor
Pitavastatin is a potent HMG-CoA reductase inhibitor that effectively reduces cholesterol synthesis from acetic acid, demonstrating an IC50 of 5.8 nM in HepG2 cells. This compound functions as a potent inducer of low-density lipoprotein-cholesterol (LDL-C) receptors in hepatocytes. Additionally, Pitavastatin exhibits a broad range of biological activities, including anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects, making it valuable for research in cardiovascular health and metabolic disorders. -
HMG-CoA Reductase Inhibitor
(3R,5S)-Fluvastatin sodium is a potent competitive inhibitor of HMG-CoA reductase, displaying an IC50 value of 8 nM. This compound is effective in modulating lipid levels and exhibits protective effects on vascular smooth muscle cells by activating the Nrf2-dependent antioxidant pathway, mitigating oxidative stress. It is widely utilized in cardiovascular research and studies focusing on cholesterol metabolism and oxidative stress responses. -
HMG-CoA Reductase Inhibitor
(3R,5R)-Rosuvastatin is a competitive inhibitor of HMG-CoA reductase, exhibiting an IC50 value of 11 nM. This compound is known for its ability to significantly reduce levels of low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein. Additionally, (3R,5R)-Rosuvastatin has been shown to inhibit human ether-a-go-go related gene (hERG) currents with an IC50 of 195 nM, impacting hERG protein expression and its interactions with heat shock protein 70 (Hsp70). Its pharmacological profile makes it valuable for research related to cholesterol management and cardiovascular health. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Rosuvastatin is a competitive inhibitor of HMG-CoA reductase, exhibiting an IC50 of 11 nM. This agent plays a significant role in reducing low-density lipoprotein (LDL) cholesterol and triglyceride levels while decreasing C-reactive protein levels. Additionally, (3S,5R)-Rosuvastatin inhibits the hERG channel with an IC50 of 195 nM and modulates the expression of the hERG protein through the disruption of its interaction with heat shock protein 70 (Hsp70). This compound is valuable in cardiovascular research and studies focused on cholesterol metabolism. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Fluvastatin-d6 is a deuterium-labeled derivative of the HMG-CoA reductase inhibitor, Fluvastatin. As a competitive inhibitor with an IC50 of 8 nM, it effectively regulates cholesterol biosynthesis. This compound has been shown to protect vascular smooth muscle cells from oxidative stress via the Nrf2-dependent antioxidant pathway, making it a valuable tool in cardiovascular research and studies focused on oxidative damage and cellular stress responses. -
HMG-CoA Reductase Inhibitor
Atorvastatin strontium is an HMG-CoA reductase inhibitor that effectively lowers cholesterol levels, impacting cardiovascular health. Its primary mechanism involves the inhibition of HMG-CoA reductase in liver tissue, which plays a crucial role in cholesterol synthesis. This compound is also utilized in research to address dyslipidemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor that effectively reduces blood lipid levels. This compound demonstrates the ability to inhibit human smooth muscle cell proliferation and invasion, with IC50 values of 0.39 μM and 2.39 μM, respectively. Its capacity to modulate lipid metabolism makes it significant for research in cardiovascular diseases and metabolic disorders. -
HMG-CoA Synthase Inhibitor
Hymeglusin is a fungal β-lactone antibiotic that functions as a potent inhibitor of HMG-CoA synthase, exhibiting an IC50 of 0.12 μM. This compound covalently modifies the active cysteine residue at position 129 of the enzyme, thereby disrupting its activity. Hymeglusin is primarily utilized in research applications focused on lipid metabolism and studying the modulation of cholesterol biosynthesis pathways. -
α-Glucosidase/HMG-CoA reductase Dual Inhibitor
Ganomycin I is a dual inhibitor targeting α-Glucosidase and HMG-CoA reductase. It demonstrates significant anti-diabetic properties and inhibits HIV protease, contributing to its potential as an antiviral agent. Additionally, Ganomycin I shows effectiveness in preventing osteoclastogenesis, making it a valuable reagent for research in diabetes and bone metabolism. -
Precursor of HMG-CoA
Acetoacetyl-CoA is a key precursor of HMG-CoA in the mevalonate pathway, playing a crucial role in cholesterol biosynthesis. It is generated through the action of acetoacetyl-CoA thiolase, which catalyzes the condensation of two acetyl-CoA molecules. Additionally, acetoacetyl-CoA serves as an important intermediate in the metabolism of fatty acids, contributing to both their breakdown and synthesis. This compound is valuable for research in lipid metabolism and the regulation of cholesterol levels. -
HMG-CoA Reductase Inhibitor
(Rac)-5-Keto Fluvastatin is a specific impurity of Fluvastatin, functioning primarily as an HMG-CoA reductase inhibitor. With an IC50 value of 8 nM, it demonstrates potent inhibitory activity against this key enzyme involved in cholesterol biosynthesis. This compound is useful for studies focused on lipid metabolism and cardiovascular research, enabling the investigation of statin-related mechanisms and effects. -
HMG-CoA Inhibitor
L-669,262 is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, exhibiting an IC50 of 0.10 ng/mL in rat liver preparations. This compound effectively downregulates cholesterol synthesis, making it a valuable tool in lipid metabolism research and studies focused on cardiovascular disease. Its specificity and high potency facilitate a wide range of applications in pharmacological studies and drug development targeting dyslipidemia. -
HMG-CoA Reductase Inhibitor
Pitavastatin magnesium is a potent HMG-CoA reductase inhibitor that plays a critical role in lipid metabolism. It effectively reduces total cholesterol and low-density lipoprotein cholesterol levels, as demonstrated in hyperlipidemic rat models. This compound is valuable for research focused on cardiovascular and cerebrovascular diseases, particularly in studies investigating hyperlipidemia and its associated conditions. -
HMG-CoA Reductase (HMGCR) Inhibitor
L 668411 is a β-lactone compound that acts as an inhibitor of HMG-CoA Reductase (HMGCR), targeting cholesterol biosynthesis. It effectively inhibits rat liver cytosolic 3-hydroxy-3-methylglutaryl-CoA synthase and reduces [14C] acetate incorporation into sterols in Hep G2 cell cultures. The inhibition demonstrates an irreversible mechanism in cellular systems, while exhibiting reversible properties in cultured cells and animal models, making it a valuable tool for studying cholesterol metabolism and related diseases. -
HMG-CoA Reductase Inhibitor
Tenivastatin calcium is an HMG-CoA reductase inhibitor that effectively lowers cholesterol levels by inhibiting the rate-limiting step in cholesterol biosynthesis. This compound has potential applications in the study of hyperlipidemia and cardiovascular disease, providing insights into lipid metabolism and associated disorders. Researchers can utilize Tenivastatin calcium to explore therapeutic strategies aimed at managing lipid abnormalities. -
HMG-CoA Reductase Inhibitor
Glenvastatin is a potent inhibitor of HMG-CoA reductase, an enzyme critical in the cholesterol biosynthesis pathway. This compound effectively reduces plasma levels of total cholesterol and phospholipids, as well as liver cholesterol content, without increasing cholesterol or total bile acids in gallbladder bile. Glenvastatin is valuable for research focused on hyperlipidemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Fluvastatin-d6 sodium is a deuterium-labeled derivative of the HMG-CoA reductase inhibitor, (3S,5R)-Fluvastatin. This compound exhibits a potent inhibitory activity with an IC50 of 8 nM, making it valuable for studying cholesterol biosynthesis. In addition to its role in lipid regulation, Fluvastatin has been shown to protect vascular smooth muscle cells from oxidative stress via the Nrf2-dependent antioxidant pathway, offering insights for cardiovascular research applications. -
HMG-CoA Reductase Inhibitor
Dalvastatin is a potent inhibitor of HMG-CoA reductase, a key enzyme involved in cholesterol biosynthesis. By effectively reducing cholesterol levels, Dalvastatin demonstrates significant potential in the management of hyperlipidemia and related cardiovascular conditions. Its ability to modulate lipid profiles makes it a valuable tool for research into lipid metabolism and cardiovascular disease therapeutics. -
HMG-CoA Reductase Inhibitor
GR 92549 is a potent, orally active inhibitor of HMG-CoA reductase, targeting the enzyme responsible for cholesterol biosynthesis. This compound effectively reduces cholesterol levels and may serve as a significant tool in metabolic and cardiovascular research. Its capability to modulate cholesterol metabolism makes it valuable for studies related to dyslipidemia and atherosclerosis. -
HMG-CoA Reductase (HMGCR) Control
((3R,5R,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate) calcium(II) is a control compound associated with HMG-CoA reductase (HMGCR), a key enzyme involved in cholesterol biosynthesis. This compound serves as an impurity marker in the analysis of Rosuvastatin, an established HMGCR inhibitor. Its role in research applications includes evaluating batch consistency and the purity of statin formulations, facilitating the development and quality control of lipid-lowering therapeutics. -
HMG-CoA Reductase (HMGCR) Inhibitor
Rawsonol is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a key enzyme in the cholesterol biosynthesis pathway. Derived from the green alga Avrainuika rawsoni, Rawsonol demonstrates significant inhibitory activity, making it a valuable tool for research investigating cholesterol regulation and related metabolic pathways. Its role as an HMGCR inhibitor positions it for applications in studies of lipid metabolism and cardiovascular health. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Pitavastatin calcium functions primarily as an inhibitor of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. This enantiomer exhibits significant lipid-lowering activity, making it valuable for research into dyslipidemia and cardiovascular disease. Its efficacy in modulating lipid profiles has led to its application in studies focused on metabolic disorders and therapeutic approaches for hypercholesterolemia. -
HMG-CoA reductase Inhibitor
Atorvastatin (lysine) is a potent inhibitor of HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. This compound is primarily utilized in research focused on hypercholesterolemia and mixed hyperlipidemia, enabling studies on lipid regulation and cardiovascular health. Its ability to modulate cholesterol levels makes it valuable for investigating therapeutic approaches for dyslipidemia-related conditions. -
HMG-CoA Reductase Inhibitor
BMS-180431 is a potent inhibitor of HMG-CoA reductase, with an IC50 value of 43 nM. This compound effectively reduces cholesterol biosynthesis, making it relevant for research in lipid metabolism and cardiovascular disease. It is applicable in studies exploring hyperlipidemia, atherosclerosis, and related metabolic disorders. -
HMG-CoA Reductase (HMGCR) Inhibitor
Lovastatin hydroxy acid sodium is a potent inhibitor of HMG-CoA reductase (HMGCR), exhibiting a Ki of 0.6 nM. By effectively blocking the enzymatic action of HMGCR, this compound plays a critical role in cholesterol biosynthesis regulation. It is widely utilized in research to explore lipid metabolism, cardiovascular diseases, and therapeutic interventions for dyslipidemia. -
HMG-CoA Inhibitor
Pravastatin lactone is a potent HMG-CoA reductase inhibitor that functions as a metabolite of pravastatin. It effectively decreases blood cholesterol levels by inhibiting the synthesis of cholesterol in the liver. This compound is widely used in research related to lipid metabolism, cardiovascular diseases, and the development of cholesterol-lowering therapies. -
HMG-CoA Reductase (HMGCR) Inhibitor
β-Amyrin palmitate is an HMG-CoA reductase (HMGCR) inhibitor that plays a crucial role in lipid metabolism. This compound exhibits biological activity that can aid in the management of diabetes mellitus, making it a valuable reagent for research in metabolic disorders. Its ability to modulate cholesterol biosynthesis may also offer insights into cardiovascular health and related conditions.
